Search Results

Boca Raton, FL, February 18, 2026 (Globe Newswire) -- LIXTE Biotechnology Holdings, Inc., a clinical-stage oncology company developing small-molecule cancer therapies and radiotherapy technologies, announced the appointment of Sidney Braun as Chief Executive Officer of its European subsidiary, Liora Technologies Europe Ltd.. Braun brings more than two decades of healthcare operational and strategic experience and previously played a key role in establishing Liora and facilitating LIXTE’s acquisition of its assets in November 2025 from Orbit Capital, Inc. Read full article here .

Waltham, MA, February 18, 2026 (Business Wire) -- Korsana Biosciences announced it has emerged from stealth mode with $175 million in total funding to advance novel therapies for neurodegenerative diseases, initially focusing on Alzheimer’s disease. The financing includes a $25 million seed round in 2024 led by Fairmount and Venrock Healthcare Capital Partners, followed by a $150 million Series A in September 2025 co-led by Wellington Management and TCGX, with participation from J.P. Morgan Life Sciences Private Capital, Janus Henderson Investors, Sanofi Ventures, and Foresite Capital. The company expects its current capital to support operations through key clinical milestones in 2027, with runway extending into 2028. Read full article here .

Paris, February 12, 2026 (Sanofi) -- Sanofi has named Belen Garijo as its next Chief Executive Officer, following the Board’s decision not to renew Paul Hudson’s mandate. Hudson will step down on February 17, 2026, after six years leading the company’s strategic transformation. Garijo will officially assume the CEO role after the Annual General Meeting on April 29, 2026, subject to shareholder approval of her nomination to the Board. During the interim period, Olivier Charmeil will serve as Interim CEO. Currently CEO of Merck KGaA, Garijo made history in 2021 as the first woman to lead a DAX40-listed company in Germany. A medical doctor by training, she began her career in hospital medicine before moving into the pharmaceutical industry, holding leadership roles in R&D at Abbott Laboratories and spending 15 years at Sanofi in senior operational positions, including Vice President of Pharmaceutical Operations for Europe and Canada and member of the Executive Committee. Read full article here .

Washington, February 17, 2026 (PRNewswire) -- Danaher Corporation announced it has signed a definitive agreement to acquire Masimo Corporation, a leader in pulse oximetry and advanced patient monitoring technologies, in an all-cash deal valued at approximately $9.9 billion, including assumed debt. Under the agreement, Danaher will pay $180 per share in cash, representing a transaction multiple of roughly 18x estimated 2027 EBITDA, or 15x including expected synergies. Masimo will operate as a standalone company within Danaher’s Diagnostics segment, joining businesses such as Radiometer, Leica Biosystems, Cepheid, and Beckman Coulter Diagnostics. Read full article here .

Franklin Lakes, NJ, February 9, 2026 (PRNewswire) -- BD said it has completed the spin-off of its Biosciences & Diagnostic Solutions business and combined it with Waters Corporation, finalizing the previously announced transaction. At closing, BD shareholders received Waters shares representing 39.2% of the combined company (fully diluted), and BD said the business was valued at $18.8B based on Waters’ Feb. 6, 2026 closing price. BD also said it plans to deploy $2B toward an accelerated share repurchase program and use the remaining $2B to pay down debt in the near term, subject to market conditions. Read full article here .

Boston and Toronto, February 10, 2026 (Globe Newswire) -- Helus Pharma named Michael Cola Chief Executive Officer, effective immediately, as the company shifts into a “scale and execution” phase. Cola previously led Shire’s Specialty Pharmaceutical business and brings 30+ years across neuroscience, rare disease, and specialty pharma, with experience spanning late-stage development and global commercialization. The company said the timing aligns with upcoming milestones, including expected Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 in Q4 2026, alongside an expanding IP estate of hundreds of patent filings. Read full article here .

Millbrae, CA, February 4, 2026 (Globe Newswire) -- Eikon Therapeutics set the price for an upsized initial public offering of 21,177,600 common shares at $18.00 each and granted underwriters a 30-day option to buy up to 3,176,640 additional shares. The company expects gross proceeds of roughly $381 million before fees and expenses (excluding any proceeds from the option), with trading anticipated to begin on Feb. 5, 2026, subject to customary closing conditions. Read full article here .

Chelmsford, M A, February 4, 2026 (ZOLL) -- ZOLL Medical (an Asahi Kasei company) appointed Eric Knudsen as Chief Executive Officer, effective April 1, 2026. Knudsen will succeed Jon Rennert, who led ZOLL for the past 10 years and will move into the role of Executive Chairman of the Board. ZOLL highlighted Knudsen’s nearly 30 years in medtech, including leading corporate development at ZOLL and most recently serving as President of ZOLL Itamar, where he oversaw significant growth and improved profitability. Read full article here .

Indianapolis and Watertown, MA, February 9, 2026 (PRNewswire) -- Eli Lilly signed a definitive agreement to acquire Orna Therapeutics, adding a circular RNA + lipid nanoparticle platform designed to engineer immune cells inside the body rather than via traditional ex vivo manufacturing. Read full article here .

San Francisco, CA, January 22, 2026 (Business Wire) -- Mendra launched with an oversubscribed $82 million Series A financing to acquire, develop, and commercialize therapies for rare diseases with high unmet need. The round was co-led by OrbiMed, 8VC, and 5AM Ventures, with participation from Lux Capital and Wing VC. The company plans to leverage artificial intelligence to accelerate patient identification, clinical trial enrollment, and global commercialization as it builds an initial portfolio of rare disease assets. Read full article here .

Kingston, NY, January 27, 2026 (PRNewswire) -- Millrock Technology has appointed Tom Hochuli as Chief Executive Officer, bringing more than 30 years of leadership across life sciences, medical devices, and biologics manufacturing. Hochuli joins at a pivotal growth stage and is expected to strengthen Millrock’s position as a trusted innovator in advanced freeze-drying and processing technologies for pharma and biotech customers. His background includes leading operational transformations, scaling GMP manufacturing organizations, and guiding private equity-backed businesses through expansion and successful exits. Read full article here .

Minneapolis & Brisbane, January 22, 2026 (Globe Newswire) -- Anteris Technologies Global Corp. announced a $90 million strategic investment from Medtronic, bringing total gross proceeds to $320 million when combined with a concurrent underwritten equity offering. The funding will support execution of Anteris’ global pivotal PARADIGM trial and accelerate progress toward worldwide commercialization of its DurAVR® transcatheter heart valve for aortic stenosis. Company leaders said the investment validates Anteris’ valve technology and could broaden into deeper strategic collaboration as both firms aim to advance durability, hemodynamics, and long-term outcomes in the TAVR market. Read full article here .